ArticleBritish journal of cancer2010

Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer.

N M Corcoran et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.